Mapping Which Parts of Antimicrobial Hybrid Peptides Are Essential for Killing Bacteria and Tumors

Systematic truncation and amino acid substitution of cecropin-magainin and cecropin-melittin hybrids identified the minimum structural features needed for antibacterial and antitumor activity while minimizing blood cell toxicity.

RPEP-00557In VitroPreliminary Evidence1999RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
in-vitro
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

Structure-activity analysis identified the amphipathic helix hydrophobic face as essential for antibacterial activity, tryptophan as important for antitumor activity, and specific substitutions that separate antimicrobial potency from hemolytic toxicity.

Key Numbers

How They Did This

In-vitro study synthesizing truncated peptides and amino acid substitution analogs of CA(1-8)-MA(1-12) and CA(1-8)-ME(1-12) hybrids. Antibacterial, antitumor, and hemolytic activities measured for each variant.

Why This Research Matters

These structure-activity rules provide a practical blueprint for designing antimicrobial peptides that are effective against bacteria and cancer while safe for human cells — essential for clinical drug development.

The Bigger Picture

Rational peptide drug design requires knowing which structural features are essential and which can be modified. This systematic study provides that knowledge for one of the most promising antimicrobial peptide families.

What This Study Doesn't Tell Us

In-vitro activities may not predict in-vivo drug performance. Limited bacterial and tumor cell panel. Stability and pharmacokinetics not assessed.

Questions This Raises

  • ?Can the optimized selective analogs achieve in-vivo antimicrobial efficacy?
  • ?Do these SAR rules apply to other antimicrobial peptide families?
  • ?Can computational methods use these rules to design improved variants?

Trust & Context

Key Stat:
Selectivity achieved Specific amino acid substitutions maintained antibacterial/antitumor activity while reducing blood cell toxicity — the key to safe peptide antibiotics
Evidence Grade:
Preliminary in-vitro evidence from a systematic SAR study providing consistent design rules across multiple peptide variants.
Study Age:
Published in 1999. These SAR principles have guided antimicrobial peptide development for over two decades.
Original Title:
Structure-antibacterial, antitumor and hemolytic activity relationships of cecropin A-magainin 2 and cecropin A-melittin hybrid peptides.
Published In:
The journal of peptide research : official journal of the American Peptide Society, 53(1), 82-90 (1999)
Authors:
Shin, S Y(4), Kang, J H(3), Hahm, K S(4)
Database ID:
RPEP-00557

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

Why is this important for fighting antibiotic resistance?

Bacteria develop resistance to conventional antibiotics, but antimicrobial peptides work differently. Knowing which peptide features kill bacteria allows researchers to design new antibiotics that bacteria can't easily resist.

Can these peptides treat cancer too?

Some analogs showed antitumor activity. The study identified tryptophan as important for this effect, suggesting dual-purpose peptides could be designed to fight both infections and cancer.

Read More on RethinkPeptides

Cite This Study

RPEP-00557·https://rethinkpeptides.com/research/RPEP-00557

APA

Shin, S Y; Kang, J H; Hahm, K S. (1999). Structure-antibacterial, antitumor and hemolytic activity relationships of cecropin A-magainin 2 and cecropin A-melittin hybrid peptides.. The journal of peptide research : official journal of the American Peptide Society, 53(1), 82-90.

MLA

Shin, S Y, et al. "Structure-antibacterial, antitumor and hemolytic activity relationships of cecropin A-magainin 2 and cecropin A-melittin hybrid peptides.." The journal of peptide research : official journal of the American Peptide Society, 1999.

RethinkPeptides

RethinkPeptides Research Database. "Structure-antibacterial, antitumor and hemolytic activity re..." RPEP-00557. Retrieved from https://rethinkpeptides.com/research/shin-1999-structureantibacterial-antitumor-and-hemolytic

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.